Sweet syndrome (SS), known as acute febrile neutrophilic dermatosis, is an inflammatory disorder characterised by the abrupt appearance of painful, oedematous and erythematous skin lesions. It is a relatively rare phenomenon, with unknown pathogenesis but is often associated with haematological malignancies. We present the case of a 74-year old patient with low risk myelodysplastic syndrome (MDS) (IPSS-R of three) who suffered from Sweet syndrome complicated by inflammatory ischemic events and weight loss. The patient was treated for his underlying MDS with 5-azacytidine (Vidaza) (samples obtained from Celgene) after failure of other commercially available therapies for SS. His signs and symptoms resolved in a few months and his quality of life significantly improved over time.

(BELG J HEMATOL 2021;12(4):169-72)